AGENDA

Thursday, October 14, 2 p.m.-6:30 p.m. EST

2021 *Virtual*
NEUROENDOCRINE TUMOR
RESEARCH SYMPOSIUM

SESSION 1: GASTROINTESTINAL NETs, 2-4:05 p.m. EST

Session Chairs: Ramesh Shivdasani, MD, PhD & Anil Rustgi, MD

1. **Rare Cancer Initiative Effort: A Roadmap For Neuroendocrine Tumor Dependency**
   Moony (Yuen-Yi) Tseng, Broad Institute (Eli and Edythe L. Broad Institute of MIT and Harvard)
2. **Genes that cause multifocal ileal neuroendocrine tumorigenesis and metastasis**
   Chris Harris, University of Rochester Medical Center, Wilmot Cancer Institute
3. **Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors**
   Netta Mäkinen, Dana-Farber Cancer Institute
4. **Transcriptional and chromatin cascade underlying human enteroendocrine cell differentiation**
   Pratik Singh, Dana-Farber Cancer Institute
5. **Metabolomic Profile of Gastrointestinal and Pulmonary Neuroendocrine Tumors: Prognostic and Biological Relevance**
   Anna La Salvia, Hospital Universitario 12 de Octubre
6. **Nanobody-directed CAR T cells eliminate neuroendocrine tumors without toxicity via masking of the antigen target in normal cells**
   Xianxin Hua, University of Pennsylvania

Discussion

SPECIAL NETRF PRESENTATION: THE SCIENTISTS BEHIND THE SCIENCE, 4:05-4:15 p.m. EST

SESSION 2: MULTIPLE NETs, 4:15-6:30 p.m. EST

Session Chairs: Lisa Bodei, MD, PhD & George Fisher, PhD

1. **Biodistribution and radiation dosimetry of 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors**
   Simone Krebs, Memorial Sloan Kettering Cancer Center
2. **Multimodal analogs of DOTA-JR11 to investigate the unexpected bone marrow toxicity in NET patients**
   Susanne Kossatz, Technical University Munich
3. **Engineering Decreased Nephrotoxicity for SSTR2 Targeted Alpha Therapy**
   David Morse, H. Lee Moffitt Cancer Center & Research Institute
4. **uPAR-targeted PRRT: new radionuclide-based therapy**
   Andreas Kjaer, Copenhagen University Hospital (Rigshospitalet)
5. **Digital Image Analysis in Neuroendocrine Tumors**
   Michelle Kim, Icahn School of Medicine at Mount Sinai
6. **SV2A PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Neuroendocrine Tumors**
   Guiyang Hao, UT Southwestern Medical Center
7. **SSTR2-targeted delivery of temozolomide**
   Solmaz Aghaamiri, The University of Texas Health Science Center at Houston

Discussion

AGENDA

Friday, October 15, 2021, 2 p.m.-6:30 p.m.

2021 *Virtual*
NEUROENDOCRINE TUMOR
RESEARCH SYMPOSIUM

SESSION 3: PHEO/PARA & LUNG NETs, 2-4 p.m. EST

Session Chairs: Daniel M. Halperin, MD & Carl M. Gay, MD, PhD

1. **Pheochromocytoma organoids as a model to recapitulate cell diversity and function ex vivo**
   Patricia Dahia and Alice Soragni, UT Health San Antonio and The Regents of the University of California, Los Angeles
2. **Succinate accumulation is not sufficient for tumorigenesis in mouse chromaffin cells but dual loss of SDHB and NF1 yields SDHx-like pheochromocytomas**
   Justin Annes, Stanford University
3. **Adverse effects of oxygen in a cell culture model for SDHB-mutated Pheochromocytoma/ Paraganglioma**
   Arthur Tischler, Tufts Medical Center
4. **First PET Imaging Studies with 3-[18F]fluoro-p-hydroxyphenethylguanidine ([18F]3F-PHPG) in Paraganglioma and Pheochromocytoma Patients**
   David Raffel, The Regents of the University of Michigan
5. **Organoid Models of Normal and Malignant Neuroendocrine Cells Reveal Pathways Important for Neuroendocrine Cell Growth, Differentiation, and Transformation**
   Talya Dayton, Hubrecht Institute of Developmental Biology and Stem Cell Research
6. **Tumor xenografts in zebrafish: a new in vivo model for lung carcinoids**
   Giovanni Vitale, Istituto Auxologico Italiano

Discussion

SESSION 4: PANCREAS NETs, 4-6:30 p.m. EST

Session Chairs: James Bibb, PhD & Dawn Quelle, PhD

1. **Patient-derived Islet-like Tumoroids reflect phenotypic landscape of original Pancreatic Neuroendocrine Neoplasms and facilitate in vitro drug screening**
   Simon L. April-Monn, University of Bern (Universität Bern)
2. **RABL6A-Myc signaling promotes pancreatic neuroendocrine tumor cell proliferation and survival**
   Ume Salma Shaik Amjad, The University of Iowa
3. **Loss of MEN1 function inhibits DNA repair capability of pancreatic neuroendocrine tumors**
   Xavier Keutgen, The University of Chicago
4. **Loss of Men1 and Pten promotes invasion and metastasis of pancreatic neuroendocrine tumors**
   Ziqiang Yuan, Rutgers University Foundation
5. **The Importance of DDR genes in Response to PRRT- Evidence for PARP and DNA-PK as Therapeutic Targets to Increase Efficacy**
   Rodney Hicks, Peter MacCallum Cancer Centre
6. **New pathways for targeting glucose consumption in PNET**
   Peter Clark, The Regents of the University of California, Los Angeles
7. **Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors**
   Minah Kim, Columbia University Medical Center
8. **The role of the B7x signaling pathway in the development and progression of neuroendocrine tumors**
   Steven Libutti, Rutgers, The State University of New Jersey

Discussion

End of Meeting, Elyse Gellerman